220 related articles for article (PubMed ID: 23614202)
1. [Atrial fibrillation. Apixaban reduces stroke risk].
MMW Fortschr Med; 2013 Mar; 155(4):70-1. PubMed ID: 23614202
[No Abstract] [Full Text] [Related]
2. Is Apixaban (Eliquis) the "ideal" anticoagulant to replace warfarin for stroke prevention in atrial fibrillation?
Strain J; Templeton K
S D Med; 2013 Jan; 66(1):20-1. PubMed ID: 23342716
[No Abstract] [Full Text] [Related]
3. Apixaban for stroke prevention in atrial fibrillation: a review of the clinical trial evidence.
Yates SW
Hosp Pract (1995); 2011 Oct; 39(4):7-16. PubMed ID: 22056819
[TBL] [Abstract][Full Text] [Related]
4. Apixaban for the prevention of stroke in atrial fibrillation.
Littrell R; Flaker G
Expert Rev Cardiovasc Ther; 2012 Feb; 10(2):143-9. PubMed ID: 22292869
[TBL] [Abstract][Full Text] [Related]
5. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY
Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583
[TBL] [Abstract][Full Text] [Related]
6. An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.
Mantha S; Ansell J
Thromb Haemost; 2012 Sep; 108(3):476-84. PubMed ID: 22740145
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of apixaban compared with aspirin for stroke prevention in atrial fibrillation among patients unsuitable for warfarin.
Lee S; Anglade MW; Meng J; Hagstrom K; Kluger J; Coleman CI
Circ Cardiovasc Qual Outcomes; 2012 Jul; 5(4):472-9. PubMed ID: 22740012
[TBL] [Abstract][Full Text] [Related]
8. Apixaban versus warfarin in patients with atrial fibrillation according to prior warfarin use: results from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial.
Garcia DA; Wallentin L; Lopes RD; Thomas L; Alexander JH; Hylek EM; Ansell J; Hanna M; Lanas F; Flaker G; Commerford P; Xavier D; Vinereanu D; Yang H; Granger CB
Am Heart J; 2013 Sep; 166(3):549-58. PubMed ID: 24016506
[TBL] [Abstract][Full Text] [Related]
9. Stroke risk and efficacy of apixaban in atrial fibrillation patients with moderate chronic kidney disease.
Eikelboom JW; Connolly SJ; Gao P; Paolasso E; De Caterina R; Husted S; O'Donnell M; Yusuf S; Hart RG
J Stroke Cerebrovasc Dis; 2012 Aug; 21(6):429-35. PubMed ID: 22818021
[TBL] [Abstract][Full Text] [Related]
10. Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale.
Lopes RD; Alexander JH; Al-Khatib SM; Ansell J; Diaz R; Easton JD; Gersh BJ; Granger CB; Hanna M; Horowitz J; Hylek EM; McMurray JJ; Verheugt FW; Wallentin L;
Am Heart J; 2010 Mar; 159(3):331-9. PubMed ID: 20211292
[TBL] [Abstract][Full Text] [Related]
11. ARISTOTLE expands the list of novel anticoagulants for thromboprophylaxis in atrial fibrillation.
Tzeis S; Andrikopoulos G
Angiology; 2012 Oct; 63(7):558-9. PubMed ID: 22669951
[No Abstract] [Full Text] [Related]
12. Apixaban (Eliquis)--a new oral anticoagulant for atrial fibrillation.
Med Lett Drugs Ther; 2013 Feb; 55(1409):9-10. PubMed ID: 23381226
[No Abstract] [Full Text] [Related]
13. Outcomes of apixaban vs. warfarin by type and duration of atrial fibrillation: results from the ARISTOTLE trial.
Al-Khatib SM; Thomas L; Wallentin L; Lopes RD; Gersh B; Garcia D; Ezekowitz J; Alings M; Yang H; Alexander JH; Flaker G; Hanna M; Granger CB
Eur Heart J; 2013 Aug; 34(31):2464-71. PubMed ID: 23594592
[TBL] [Abstract][Full Text] [Related]
14. Contra: "New oral anticoagulants should not be used as 1st choice for secondary stroke prevention in atrial fibrillation".
Stöllberger C; Finsterer J
Thromb Haemost; 2013 Sep; 110(3):496-500. PubMed ID: 23803875
[No Abstract] [Full Text] [Related]
15. Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis.
Harenberg J; Marx S; Diener HC; Lip GY; Marder VJ; Wehling M; Weiss C
Int Angiol; 2012 Aug; 31(4):330-9. PubMed ID: 22801398
[TBL] [Abstract][Full Text] [Related]
16. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation.
Lip GY; Larsen TB; Skjøth F; Rasmussen LH
J Am Coll Cardiol; 2012 Aug; 60(8):738-46. PubMed ID: 22575324
[TBL] [Abstract][Full Text] [Related]
17. Apixaban (eliquis) for stroke prevention in atrial fibrillation.
Beck RA; King WM
Am Fam Physician; 2014 Apr; 89(8):672-5. PubMed ID: 24784127
[No Abstract] [Full Text] [Related]
18. Pro: "The novel oral anticoagulants should be used as 1st choice for secondary prevention in patients with atrial fibrillation.".
Diener HC
Thromb Haemost; 2013 Sep; 110(3):493-5. PubMed ID: 23803957
[No Abstract] [Full Text] [Related]
19. [Prevention of stroke in nonvalvular atrial fibrillation. Oral direct factor Xa inhibitor apixaban: positive experiences in general medical practice].
MMW Fortschr Med; 2013 Sep; 155(16):62-3. PubMed ID: 24279159
[No Abstract] [Full Text] [Related]
20. Critique of apixaban versus warfarin in patients with atrial fibrillation.
Nedeltchev K
Stroke; 2012 Mar; 43(3):922-3. PubMed ID: 22308243
[No Abstract] [Full Text] [Related]
[Next] [New Search]
